Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease

SILVA, MARCELO O.; RIDRUEJO, EZEQUIEL; MENDIZABAL, MANUEL

HEMODIALYSIS INTERNATIONAL

WILEY-BLACKWELL PUBLISHING, INC

Año: 2018 vol. 22 p. 97 - 103

1492-7535

Hepatitis C virus infection (HCV) is highly prevalent in patients with chronic kidney disease (CKD) and kidney transplant recipients. Little information exists on treatment in patients with CKD stages 2 to 3, where CKD progression might be slowed by HCV treatment. These patients are not considered a high priority for HCV treatment in most international guidelines. Although some recently published guidelines propose universal treatment, others are still recommending it only in high priority groups. In this review, we evaluate current evidence of HCV infection impact on CKD progression, on cardiovascular and metabolic risk, and the benefits of HCV infection treatment to improve cardiovascular and metabolic outcomes. We made special focus on the benefits of HCV infection treatment in patients with stages 2 to 3 CKD to avoid CKD progression.